Olanzapine pharmacokinetics are similar in Chinese and Caucasian subjects

被引:26
作者
Sathirakul, K
Chan, C
Teng, LY
Bergstrom, RF
Yeo, KP
Wise, SD
机构
[1] Natl Univ Singapore, Lilly NUS Ctr Clin Pharmacol, Singapore 117597, Singapore
[2] Eli Lilly & Co, Indianapolis, IN 46285 USA
关键词
CYP1A2; olanzapine; pharmacokinetics; race;
D O I
10.1046/j.1365-2125.2003.01857.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aim To compare the pharmacokinetic profiles and dose proportionality of olanzapine in Chinese and Caucasian subjects. Methods Randomized, three-period study with 12 Chinese and 12 Caucasian, healthy, male subjects administered 2.5, 5 and 10 mg olanzapine. Non compartmental pharmacokinetic parameters were derived. Results No statistically significant racial differences in the weight-normalized pharmacokinetic parameters were observed except for V-z/F-norm, or which was 17% lower at the 5- and 10-mg dose in the Chinese group (95% confidence interval 8.49, 10.1 and 8.05, 9.73, respectively), compared with the Caucasian group (9.53, 12.8 and 9.39, 12.0, respectively). Olanzapine's pharmacokinetics were linear and dose proportional in both racial groups. Conclusion The pharmacokinetics of olanzapine are similar in both Chinese and Caucasian racial groups.
引用
收藏
页码:184 / 187
页数:4
相关论文
共 11 条
[1]   The influence of ethnic factors and gender on CYP1A2-mediated drug disposition: A comparative study in Caucasian and Chinese subjects using phenacetin as a marker substrate [J].
Bartoli, A ;
Xiaodong, S ;
Gatti, G ;
Cipolla, G ;
Marchiselli, R ;
Perucca, E .
THERAPEUTIC DRUG MONITORING, 1996, 18 (05) :586-591
[2]   Olanzapine - Pharmacokinetic and pharmacodynamic profile [J].
Callaghan, JT ;
Bergstrom, RF ;
Ptak, LR ;
Beasley, CM .
CLINICAL PHARMACOKINETICS, 1999, 37 (03) :177-193
[3]   ANALYSIS OF OLANZAPINE IN HUMAN PLASMA UTILIZING REVERSED-PHASE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH ELECTROCHEMICAL DETECTION [J].
CATLOW, JT ;
BARTON, RD ;
CLEMENS, M ;
GILLESPIE, TA ;
GOODWIN, M ;
SWANSON, SP .
JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS, 1995, 668 (01) :85-90
[4]   DIAZEPAM EFFECTS AND KINETICS IN CAUCASIANS AND ORIENTALS [J].
GHONEIM, MM ;
KORTTILA, K ;
CHIANG, CK ;
JACOBS, L ;
SCHOENWALD, RD ;
MEWALDT, SP ;
KAYABA, KO .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1981, 29 (06) :749-756
[5]   Influence of race or ethnicity on pharmacokinetics of drugs [J].
Johnson, JA .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1997, 86 (12) :1328-1333
[6]   USE OF CAFFEINE METABOLITE RATIOS TO EXPLORE CYP1A2 AND XANTHINE-OXIDASE ACTIVITIES [J].
KALOW, W ;
TANG, BK .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1991, 50 (05) :508-519
[7]  
Landi M T, 1999, IARC Sci Publ, P173
[8]   Glucuronidation of olanzapine by cDNA-expressed human UDP-glucuronosyltransferases and human liver microsomes [J].
Linnet, K .
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2002, 17 (05) :233-238
[9]   A pharmacokinetic interaction between carbamazepine and olanzapine: observations on possible mechanism [J].
Lucas, RA ;
Gilfillan, DJ ;
Bergstrom, RF .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 54 (08) :639-643
[10]   Review of recent clinical studies with olanzapine [J].
Tollefson, GD ;
Kuntz, AJ .
BRITISH JOURNAL OF PSYCHIATRY, 1999, 174 :30-35